Skip to content

A randomized controlled clinical study evaluating the safety and efficacy of combined treatment with 1565nm non-ablative fractional laser, 2940nm Er:YAG non-ablative fractional laser, and minoxidil for androgenic alopecia in adult males.

A randomized controlled clinical study evaluating the safety and efficacy of combined treatment with 1565nm non-ablative fractional laser, 2940nm Er:YAG non-ablative fractional laser, and minoxidil for androgenic alopecia in adult males.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106294
Enrollment
Unknown
Registered
2025-07-22
Start date
2025-07-31
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia

Interventions

The 1565nm non-ablative fractional laser combined with minoxidil treatment group:1565nm Non-Ablative Fractional Laser Treatment
The 2940nm Er:YAG Non-Ablative Fractional Laser Combined with Minoxidil Treatment Group:2940nm Er:YAG Non-Ablative Fractional Laser
Minoxidil Monotherapy Group:Minoxidil Monotherapy

Sponsors

Peking University People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Chinese adult males aged 18-50; 2.Patients clinically diagnosed with androgenetic alopecia and classified as Hamilton-Norwood grades IIIv, IV, and V; 3.The scalp is healthy, with no severe skin diseases or infections; 4.The subjects are willing to maintain the same hairstyle, hair color, and hair length during each follow-up visit; 5.Sign the informed consent form, indicating willingness to participate in the study and abide by the study regulations.

Exclusion criteria

Exclusion criteria: 1.Cannot tolerate laser treatment; 2.Individuals who are allergic to minoxidil; 3.Individuals with severe heart, liver, kidney diseases, or mental disorders; 4.Individuals who have recently undergone other treatments for hair loss (having taken oral finasteride within the 18 months prior to study screening, taken oral finasteride within the past year, or used topical medications with hair growth effects such as minoxidil within the past six months); 5.Men who plan to have children in the near future; 6.Those who cannot cooperate with the research or follow-up.

Design outcomes

Primary

MeasureTime frame
Change in Terminal Hair Count in the Target Area (TAHC);

Secondary

MeasureTime frame
Changes in Patient Disease Grading;Self-Rating of Study Participant Satisfaction;Changes in the Ratio of Terminal Hair to Vellus Hair in the Target Area;TAHC (Terminal Hair Count) Change Rate;Average Change in TAHC;

Countries

China

Contacts

Public ContactYuxin Wang

Peking University People’s Hospital

wyx_0716@163.com+86 150 0125 9951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026